PHARMACEUTICALS
Untitled Page
Zevalin expansion gets FDA approval, continued ...
“We believe the approval of Zevalin as an effective treatment option following a first-line regimen represents a notable advance in the treatment of non-Hodgkin’s Lymphoma,” says Rajesh C. Shrotriya, M.D., chairman, CEO and president of the company.
The updated indication was based on data collected during the First-line Indolent Therapy Study, which evaluated the safety and efficacy of the treatment in more than 400 patients with follicular Non-Hodgkin's lymphoma who had achieved a partial or complete response following a chemotherapy regimen. The three and one-half year follow-up found that when the drug is used as part of first-line chemotherapy for these patients, Zevalin improved the progression-free survival time from 18 months to 38 months.
Spectrum Pharmaceuticals is a commercial-stage biotechnology company that focuses in oncology.
<< PREVIOUS PAGE
Related headlines
Orange's St. Joseph Hospital debuts revolutionary procedure
'OC METRO Minute,' Sept. 3: Visiogen set to be acquired by Abbot for $400 million
O.C. Affiliate of Susan G. Komen for the Cure launches Race Registration Suite
Zevalin expansion gets FDA approval, continued ...
“We believe the approval of Zevalin as an effective treatment option following a first-line regimen represents a notable advance in the treatment of non-Hodgkin’s Lymphoma,” says Rajesh C. Shrotriya, M.D., chairman, CEO and president of the company.The updated indication was based on data collected during the First-line Indolent Therapy Study, which evaluated the safety and efficacy of the treatment in more than 400 patients with follicular Non-Hodgkin's lymphoma who had achieved a partial or complete response following a chemotherapy regimen. The three and one-half year follow-up found that when the drug is used as part of first-line chemotherapy for these patients, Zevalin improved the progression-free survival time from 18 months to 38 months.
Spectrum Pharmaceuticals is a commercial-stage biotechnology company that focuses in oncology.
<< PREVIOUS PAGE
Related headlines
Orange's St. Joseph Hospital debuts revolutionary procedure
'OC METRO Minute,' Sept. 3: Visiogen set to be acquired by Abbot for $400 million
O.C. Affiliate of Susan G. Komen for the Cure launches Race Registration Suite
